After I posted about WAIC last week, a few people sent me variations of the same question: is this just an AI story, or is there something more structural happening?
I think there’s something more structural. And healthcare might be where it’s most visible right now.
Here’s the pattern I keep noticing: when a system develops faster than the information channels that describe it, a perception gap opens. The system moves. The description of the system doesn’t move as quickly. The gap between the two is where a lot of consequential decisions get made badly.
This isn’t unique to China. It happens with any fast-developing system. But in China’s case, a few factors make the gap particularly wide — and particularly persistent.
The first is structural. Most primary sources — clinical data, hospital reports, regulatory filings — are in Chinese. The international coverage that does exist tends to cluster around a small set of narratives. The picture assembled outside is built from a limited sample.
The second is domain-specific. Healthcare information travels differently than technology information. A new software product generates English blog posts, GitHub repositories, and press releases within days. A new clinical protocol generates a peer-reviewed paper eighteen months later, in a journal that most patients will never read. The information infrastructure of healthcare is slower, more closed, and more local than almost any other domain.
The result: capabilities that are real, documented, and already operating at scale — largely invisible to the audiences most affected by them.
A few data points worth sitting with:
CAR-T cell therapy is now available in China at a fraction of the cost of equivalent treatments in the United States — in some cases, under a third of US list price. Same mechanism. Comparable clinical outcomes. NMPA-approved. This is not a future projection. It is happening now.
Oncology drug approvals in China have accelerated significantly. Several drugs now move from Phase III data to NMPA approval within 18 to 24 months — a timeline comparable to the FDA, and one that would have been unthinkable a decade ago.
International patient departments at major Shanghai hospitals have seen sustained inflows from Southeast Asian patients, particularly in oncology and complex surgical cases. These aren’t tourists. These are patients making serious, high-stakes decisions — and arriving at conclusions that differ from what the international system’s default assumptions would predict.
None of this is secret. It’s in the data. The question is why more of it isn’t in the conversation.
One answer: perception gaps have beneficiaries. Incumbent referral systems, established medical tourism corridors, any intermediary whose positioning depends on information scarcity — all benefit, in some measure, from the gap persisting. Not by design. Just by the normal friction of a status quo that hasn’t been disrupted yet.
The other answer is simpler: the people who would most benefit from knowing don’t have easy access to the channels where this information lives. A patient in Kuala Lumpur or Cairo facing a treatment decision is not reading Chinese medical journals or tracking NMPA approvals. They’re asking their oncologist, their family, and maybe a Facebook group.
Perception gaps close when two things happen simultaneously: capabilities stabilize, and information channels catch up. Chinese healthcare is approaching that inflection point — not because of any single policy or institution, but because the combination of scale, cost, and clinical outcome data is becoming hard to ignore.
Perception catches up eventually. The question is who moves first when it does.
